# Pulmonary arterial hypertension after congenital heart defect correction: a call for timely diagnosis and careful risk stratification to improve outcomes

## TL;DR

Late diagnosis of pulmonary arterial hypertension after congenital heart defect repair is common and linked to poor outcomes, highlighting the need for early detection and careful risk assessment.

## Contribution

This study provides insights into clinical presentation and outcomes of PAH-CHDcor patients, identifying key prognostic factors like baseline pulmonary vascular resistance.

## Key findings

- PAH-CHDcor patients often have high pulmonary vascular resistance at diagnosis, which strongly predicts mortality.
- Late diagnosis (>5 years post-repair) is common in PAH-CHDcor patients.
- The GOSH prognostic score shows strong predictive power for mortality and composite endpoints in this patient group.

## Abstract

Patients with pulmonary arterial hypertension (PAH) after congenital heart disease (CHD) correction (PAH-CHDcor) are becoming the most prevalent and rapidly expanding group within PAH associated with CHD (PAH-CHD), yet data on its presentation, long-term outcomes and prognostic variables are lacking. We report on a large paediatric and adult population with PAH-CHDcor, focusing on clinical presentation and long-term survival.

We studied 127 PAH-CHDcor patients (mean age 21.5 ± 10.5 years; 74.8% female) diagnosed via cardiac catheterization from 2006 to 2022. The majority had post-tricuspid shunts (73.2%), with combined pre- and post-tricuspid (11.8%) and complex shunts (6.3%) less frequent. Pulmonary vascular resistance (PVR) at diagnosis averaged 13.2 ± 8.9 WU. Diagnosis occurred late (>5 years post-repair) in 43.3% of patients. Median follow-up was 4.0 (IQR 2.0–6.4) years. Kaplan-Meier estimates for survival at 3 and 5 years were 93.3% and 89.6%, respectively. Higher baseline PVR predicted mortality (HR 1.10, 95% CI 1.03–1.16, P = 0.003) and was the strongest multivariable predictor of a composite endpoint (death, heart failure hospitalization, or parenteral prostacyclin initiation; HR 1.11, 95% CI 1.05–1.18, P < 0.001). An exploratory application of a paediatric prognostic score (GOSH) showed excellent discriminative power for mortality (AUC 0.867) and the composite endpoint (AUC 0.856) at 5 years in this independent cohort.

Mortality and morbidity are considerable in patients with PAH-CHDcor despite modern management. Regular, careful screening of all patients with repaired CHD is essential to ensure early diagnosis and risk stratification, with proactive evidence-based treatment to improve outcomes in this expanding population.

Graphical Abstract